Nintedanib is used to treat idiopathic pulmonary fibrosis. Nintedanib targets the growth factor receptors that cause the pathological mechanism of pulmonary fibrosis, especially platelet-derived growth factor receptor (PDGFR), fibroblastic growth factor receptor (FGFR), and vascular endothelial growth factor receptor (VEGFR), by blocking the signal transmission of the fibrotic process to slow down the decline of lung function, thereby slowing the progression of idiopathic pulmonary fibrosis.
|Package details:||10g/bottle; 100g/foil bag|
It is an indolinone derivative potently blocking VEGF-, PDGF-, and FGF-receptor kinases; an indolinone as triple angiokinase inhibitors.
Fortunachem Provides Not Only Professional Chemical Products But Also Professional Help
Keeping you up-to-date with all the latest information, news, and events about Fortunachem!